Our Science
Peer Reviewed Publications
Diabetes, Obesity and Metabolism
Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Read More
Diabetes Therapy
Time in Range Estimation in Patients with Type 2 Diabetes is Improved by Incorporating Fasting and Postprandial Glucose Levels
Read More
Nature Communications
2023 March, Nature Communications: A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity
Read More
Diabetes
Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes
Read More
Nature Medicine
2022 May, Nature Medicine Comments: A new class of drug in the diabetes toolbox.
Read More
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Read More
Nature Medicine
2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
Read More
Clinical and Translational Science
2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.
Read More
Global Journal of Obesity, Diabetes and Metabolic Syndrome
2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China
Read More
Diabetes, Obesity and Metabolism
2018 February / Diabetes, Obesity and Metabolism: Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
Read More
Clinical Pharmacokinetics
2018 April / Clinical Pharmacokinetics: Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration–Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics
Read More
Lancet Diabetes Endocrinology
2018 MAY / Lancet Diabetes Endocrinology: New hope for glucokinase activators in type 2 diabetes?
Read More
Lancet Diabetes Endocrinology
2018 May / Lancet Diabetes Endocrinology: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Read More
Journal of Diabetes Research
2017 January / Journal of Diabetes Research: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus
Read More
Drug Design, Development and Therapy
2016 May / Drug Design, Development and Therapy: Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
Read More
Intractable & Rare Diseases Research
2016 October / Intractable & Rare Diseases Research: Orphan drug development in China ‒ Turning challenges into opportunities
Read More
Clinical Pharmacokinetics
2016 December / Clinical Pharmacokinetics: Translational Modeling and Simulation in Supporting Early-Phase Clinical Development of New Drug: A Learn–Research–Confirm Process
Read More
Intractable & Rare Diseases Research
2015 / Intractable & Rare Diseases Research：Fragile X syndrome as a rare disease in China – Therapeutic challenges and opportunities
Read More
Focus Us
Copyright © 2024 Hua Medicine (Shanghai) Co., Ltd. 互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x